Every 8-K that Nano Dimension (NNDM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NNDM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNDM filings page.
Nano Dimension Ltd. appointed Nadav Kidron to its Board of Directors as a Class II director effective August 16, 2026, with a term expiring at the 2026 annual meeting of stockholders and until a successor is elected and qualified. The Board determined that he qualifies as an independent director under applicable Nasdaq rules, and he will serve on both the Audit Committee and Compensation Committee.
Kidron is President, Chief Executive Officer, director and Chairman of Oramed Pharmaceuticals Inc. and holds additional board roles at several life sciences and medical technology companies. He will be compensated under Nano Dimension’s standard non-employee director arrangements, and the company will enter into an indemnification agreement with him similar to those of other directors. Separately, a 30-day exclusivity period under a non-binding term sheet with Infinite Epigenetics, Inc. expired on July 15, 2026, and the parties have not reached terms for a definitive agreement.
Nano Dimension Ltd. reported second quarter 2026 revenue of $29.0 million, up 12.1% from $25.8 million, with GAAP gross margin improving to 45.9% from 27.3%. Net loss from continuing operations narrowed to $6.8 million, and Adjusted EBITDA loss from continuing operations improved to $9.6 million. Cash, cash equivalents, deposits, restricted deposits and marketable equity securities totaled $433.3 million as of June 30, 2026.
The company advanced a strategic plan to reduce cash burn and simplify its portfolio. It agreed to sell MarkForged, Inc. to Stratasys for $42.5 million in cash and expects this, together with other strategic actions, to reduce annualized cash burn by approximately $25 million. Nano Dimension also sold its AME and Fabrica product lines for consideration of up to $12.5 million and terminated its headquarters lease, a step expected to eliminate about $38 million of future lease costs and yield roughly $25 million of cumulative net cash savings. Leadership and board changes accompanied these actions, and full year 2026 guidance has been suspended.
Nano Dimension Ltd. entered into a Settlement Agreement on July 17, 2026 with its directors and shareholder Murchinson Ltd., under which four directors (Robert Pons, David Stehlin, Dr. Joshua Rosensweig and Andrew Sriubas) resigned and three Murchinson-nominated directors (Pinchos (Paul) Fruchthandler, Moshe Rozenbaum and Eliezer Eli Tarlow) were appointed, resulting in a change in control of the company. Murchinson irrevocably withdrew its May 21, 2026 demand for an extraordinary general meeting, and the July 31, 2026 meeting was cancelled. The agreement also includes mutual releases, covenants not to pursue certain legal proceedings, and non-disparagement provisions.
In connection with the settlement, the departing directors’ resignations, including that of CEO David Stehlin, became effective immediately after execution and were stated not to be due to any disagreement over operations, policies or practices. On July 21, 2026, new director Moshe Rozenbaum, age 44 and a former VP – Corporate Development of Nano Dimension, was appointed Interim CEO. The board designated Fruchthandler and Tarlow as independent under Nasdaq rules, added both to the Audit and Compensation Committees, and appointed Mr. Borenstein as Chair of the Board.
Nano Dimension Ltd. entered into an agreement to terminate the lease for its current corporate headquarters, effective December 31, 2026, as part of broader cost savings initiatives. The long-term lease was originally signed in 2021 by MarkForged, Inc. and scheduled to run through 2031.
The company expects the termination to eliminate approximately $38 million of cumulative future lease costs through 2031. After an approximately $13 million lease termination payment, Nano Dimension projects about $25 million in cumulative net cash savings.
Separately, the previously announced sale of MarkForged, Inc. was expected to reduce annualized cash burn by approximately $15 million, including about $7.5 million of annualized lease-related savings. Management states that these actions reflect a disciplined approach to capital allocation and focus on streamlining operations, reducing cash burn and strengthening the financial position.
Nano Dimension used this update to defend and explain its proposed business combination with Infinite Epigenetics, which would pivot the business from 3D printing toward AI-powered preventive health and diagnostics. Infinite operates a CLIA-certified methylation lab, has a network of more than 7,500 healthcare providers, over 50 peer‑reviewed publications and a proprietary database of more than 120,000 biological samples. Nano emphasizes the chronic disease diagnostics market exceeds $90 billion and says Infinite’s model blends diagnostic testing with a biological AI platform built on proprietary data. The company states the contemplated transaction values Nano at net cash plus a 20% premium, with Nano shareholders retaining contingent value rights on legacy assets and receiving two seats on the combined company’s board. Management argues this offers better long-term value than liquidating and returning cash, and contrasts its detailed plan with activist Murchinson’s push to replace a majority of the board. Any definitive agreement would later be filed on Form S-4 and put to a shareholder vote.
Nano Dimension signed a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company. Nano or a successor public entity would acquire all Infinite equity in an all‑stock deal, with ownership split based on agreed valuations of each business and Nano’s net cash, including a 20% premium component for Nano.
After closing, Infinite holders are expected to own a majority of the combined company, while current Nano shareholders retain a meaningful minority stake and receive contingent value rights tied to monetization of Nano’s legacy assets. The combined company is expected to operate as Infinite Epigenetics and list on Nasdaq under the ticker “IEAI,” with the parties indicating an expected cash balance of over $400 million at closing. The term sheet includes a 30‑day exclusivity period, detailed break‑fee protections, and a structure that requires Nano shareholder approval and a Form S‑4 registration before any transaction can close.
Nano Dimension Ltd. has called an Extraordinary General Meeting of Shareholders for July 31, 2026 at its Waltham, Massachusetts address. The meeting was demanded by a group of “Proposing Shareholders” and will address both company- and shareholder-backed governance proposals.
Shareholders will vote on continuing the company’s strategic alternatives review, amending Article 39 of the Articles (requiring a 70% majority of voting power present), adding new Articles 71 and 72, and removing and replacing three directors. The Board recommends voting FOR Proposals 1 and 2 and AGAINST Proposals 3 through 6 and urges shareholders to ignore any competing proxy cards from the Proposing Shareholders. The record date for voting eligibility is June 23, 2026.
Nano Dimension Ltd. entered a definitive agreement to sell its wholly owned subsidiary MarkForged, Inc. to Stratasys Ltd. in an all-cash transaction valued at $42.5 million. This sale is a key part of Phase 2 of Nano Dimension’s three-phase strategic plan, which centers on monetizing product lines to simplify the business and strengthen the balance sheet.
The transaction is expected to reduce Nano Dimension’s annualized cash burn by approximately $15 million through direct and indirect operating cost savings. Nano Dimension will retain the Markforged Metal Binder Jetting product line, while continuing to advance Phase 3 of its plan, which involves evaluating strategic alternatives to maximize long-term shareholder value. The deal is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.
Nano Dimension Ltd. reported first quarter 2026 revenue of $29.7 million, up 106% from $14.4 million a year earlier, with GAAP gross margin of 40.8% and adjusted gross margin of 45.9%. Despite higher sales, the company posted an adjusted EBITDA loss of $12.5 million and a net loss of $69.7 million, including $40.4 million of impairment.
Cash, cash equivalents, deposits, restricted deposits and marketable equity securities totaled $441.6 million as of March 31, 2026. Management is executing a three-phase strategic plan focused on streamlining operations, monetizing product lines, and evaluating strategic alternatives to maximize long-term shareholder value.
As part of this plan, Nano Dimension sold its AME and Fabrica product lines for consideration of up to $12.5 million and expects these moves and related actions to reduce annualized cash burn by about $10 million. Given ongoing portfolio changes and the strategic review, the company has suspended its full year 2026 financial guidance.
Nano Dimension Ltd. is updating investors on its ongoing strategic alternatives review. The company has hired Guggenheim Securities to help evaluate and execute opportunities to monetize its product lines, and Houlihan Lokey to assess alternatives related to its financial resources and public company platform.
Potential paths include a strategic merger, a reverse merger, or other strategic transactions aimed at maximizing shareholder value in 2026 and beyond. The company has identified multiple potential counterparties and is actively discussing a range of transaction structures. On April 6, 2026, it announced the sale of its additively manufactured electronics (AME) and Fabrica product lines to Inspira Technologies OXY B.H.N. Ltd. as an initial monetization step, and it plans to continue updating investors as the review progresses.
Nano Dimension Ltd. has agreed to sell its additively manufactured electronics (AME) and previously discontinued Fabrica product lines to Inspira Technologies OXY B.H.N. Ltd. for total consideration of up to $12.5 million, subject to customary regulatory approvals. The structure includes a $2.0 million upfront cash payment and up to $10.5 million in deferred payments based on the product lines’ performance over the next twelve months.
The company expects the divestiture to reduce its annualized cash burn by about $10 million, strengthen liquidity and financial flexibility, and simplify operations as part of its ongoing strategic alternatives review process to maximize shareholder value. Management determined these product lines no longer fit its go-forward priorities and plans to update 2026 financial guidance on its first quarter 2026 earnings call.
Nano Dimension Ltd. reported strong top-line growth for 2025 but remained unprofitable. Full-year 2025 revenue reached $102.4 million, up 77.3% from $57.8 million, helped by the Markforged acquisition. Fourth-quarter revenue was $35.3 million, a 142.4% increase year-over-year.
GAAP gross margin for 2025 was 33.5%, down from 43.1%, while non-GAAP adjusted gross margin improved to 46.9%. Adjusted EBITDA loss narrowed to $53.2 million from a $63.6 million loss. Net loss from continuing operations was $100.4 million, and net loss from discontinued operations, mainly related to Desktop Metal, was $193.3 million.
The company ended 2025 with $206.4 million in cash, cash equivalents and restricted cash and total cash, deposits and marketable equity securities of $459.6 million as of December 31, 2025. Non-GAAP operating expenses fell to $27.3 million in the fourth quarter, more than 16% below the prior baseline, reflecting cost-reduction efforts.
For 2026, Nano Dimension guides for revenue of $130–$140 million, non-GAAP gross margin of 46–48%, non-GAAP operating expenses of $106–$111 million and an adjusted EBITDA loss of $40–$50 million. The board’s strategic alternatives review continues, with a series of actions to define the company’s path forward expected in the second quarter of 2026.
Nano Dimension Ltd. adopted a shareholder rights plan designed to protect holders of its American Depositary Shares. The company entered into a Rights Agreement with The Bank of New York Mellon, issuing one special purchase right for each ADS outstanding at the close of business on February 13, 2026.
Each Right lets its holder buy one ADS from the company at a purchase price of $0.01 per ADS if any person or group becomes an “Acquiring Person” by beneficially owning 9.99% or more of the company’s ordinary shares, subject to detailed exceptions. Rights held by an Acquiring Person or its affiliates are void.
The Board can redeem all Rights for no consideration before anyone becomes an Acquiring Person, or later exchange exercisable Rights for ADSs at a fixed ratio, subject to limits. The Rights expire on February 1, 2027. The Board states the plan is intended to give it time to evaluate any attempt to gain significant influence and to encourage negotiations it deems in the company’s best interests.
Nano Dimension Ltd. filed a current report to share that it has issued a press release with select preliminary financial results for its fiscal fourth quarter ended December 31, 2025. The company is providing an early view of its recent operating performance, but the detailed figures appear in the accompanying press release rather than in the body of the report.
The press release is attached as Exhibit 99.1 and is treated as “furnished,” not “filed,” which means it is not subject to certain liability provisions of U.S. securities laws and is not automatically incorporated into other registration statements or reports unless specifically referenced. This filing is primarily a disclosure mechanism to make those preliminary results broadly available to the market.